Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
Stephen Boulton, Joanna Poutou, Nikolas T. Martin, Taha Azad, Ragunath Singaravelu, Mathieu J. F. Crupi, Taylor R. Jamieson, Xiaohong He, Ricardo Marius, Julia Petryk, Christiano Tanese de Souza, Bradley Austin, Zaid Taha, Jack T. Whelan, S. Khan, Adrian Pelin, Reza Rezaei, Abera Surendran, Sarah Tucker, Emily E.F. Fekete, Jaahnavi Dave, Jean‐Simon Diallo, Rebecca C. Auer, Jonathan B. Angel, D. William Cameron, Jean‐François Cailhier, Réjean Lapointe, Kyle Potts, Douglas J. Mahoney, John C. Bell, Carolina S. Ilkow
Topics & Concepts
ImmunogenicityVacciniaVirologyImmune systemCoronavirusVaccinationModified vaccinia AnkaraImmunityAntigenVirusImmunologyBiologyVaccine efficacyViral vectorMedicineDiseaseInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)Recombinant DNAGeneBiochemistryPathologySARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies